Eton Pharmaceuticals to Report Second Quarter 2021 Financial Results on Monday, August 16, 2021
Eton Pharmaceuticals, Inc. (Nasdaq: ETON) announced it will report its second quarter 2021 financial and operating results on August 16, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Eton Pharmaceuticals, Inc. (Nasdaq: ETON) announced it will report its second quarter 2021 financial and operating results on August 16, 2021. A conference call will be held at 4:30 p.m. ET to discuss these results and provide a business update. Interested parties can access the live audio webcast on Eton's investor website. Eton is focused on developing treatments for rare diseases and currently has four FDA-approved products while five additional products await FDA review.
Positive
- Eton owns or receives royalties from four FDA-approved products.
- Five additional products are submitted to the FDA for approval.
Negative
- None.
Details
News Market Reaction – ETON
The recorded move for ETON in the trading session of this news was -2.41%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DEER PARK, Ill., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report second quarter 2021 financial and operating results on Monday, August 16, 2021. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 4:30 p.m. ET (3:30 p.m. CT).
The live webcast can be accessed on the investors section of Eton’s website at https://ir.etonpharma.com/. The conference call can be accessed by dialing 1-866-795-8473 (domestic) or 1-470-495-9161 (international) and refer to conference ID 2454465. An archived webcast will be available on Eton’s website approximately two hours after the completion of the event and for 30 days thereafter.
About Eton Pharmaceuticals
Eton Pharmaceuticals, Inc. is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The company currently owns or receives royalties from four FDA-approved products, including ALKINDI® SPRINKLE, Biorphen®, Alaway® Preservative Free, and Rezipres® and has five additional products that have been submitted to the FDA.
Investor Contact:
David Krempa
dkrempa@etonpharma.com
612-387-3740
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.